Figure 2. Activation of P2Y₁₄R inhibits lipolysis in mice.

(A) Schematic representation of timeline for MRS2905 or vehicle injection (i.p.) in overnight fasted mice and blood collection for FFA assay. (B) Plasma FFA levels in HFD WT mice i.p. injected with saline or MRS2905 (10 mg/kg, i.p.). Blood was collected immediately before and 45 min after injections (n = 8 or 9/group). (C) Schematic representation of timeline for treatment of mice with vehicle or MRS4741 (20 mg/kg, i.p.). Mice were then injected with vehicle or MRS2905 (10 mg/kg, i.p.) as indicated. Blood was collected at indicated time points for FFA assay. (D) Plasma FFA (%) in control mice treated with vehicle or MRS4741 (20 mg/kg, i.p.). Mice were then injected with vehicle or MRS2905 (10 mg/kg, i.p.) as indicated. Blood was collected immediately before and 45 min after MRS2905 injections (n = 4–6/group). All data are expressed as mean ± SEM. *P < 0.05 (1-way ANOVA followed by Bonferroni’s post hoc test). All agonist/antagonist injections were conducted on WT mice maintained on an HFD for at least 8 weeks. Graphics created using Biorender.com. P2Y, purinergic; FFA, free fatty acid; HFD, high-fat diet.